| An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms HY Zou, Q Li, JH Lee, ME Arango, SR McDonnell, S Yamazaki, ... Cancer research 67 (9), 4408-4417, 2007 | 913 | 2007 |
| Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma JG Christensen, HY Zou, ME Arango, Q Li, JH Lee, SR McDonnell, ... Molecular cancer therapeutics 6 (12), 3314-3322, 2007 | 790 | 2007 |
| PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations HY Zou, Q Li, LD Engstrom, M West, V Appleman, KA Wong, M McTigue, ... Proceedings of the National Academy of Sciences 112 (11), 3493-3498, 2015 | 289 | 2015 |
| The CARMA3-Bcl10-MALT1 signalosome promotes angiotensin II-dependent vascular inflammation and atherogenesis LM McAllister-Lucas, X Jin, S Gu, K Siu, S McDonnell, J Ruland, ... Journal of Biological Chemistry 285 (34), 25880-25884, 2010 | 90 | 2010 |
| Integrated phosphoproteomic and metabolomic profiling reveals NPM-ALK–mediated phosphorylation of PKM2 and metabolic reprogramming in anaplastic large cell lymphoma SRP McDonnell, SR Hwang, D Rolland, C Murga-Zamalloa, V Basrur, ... Blood, The Journal of the American Society of Hematology 122 (6), 958-968, 2013 | 73 | 2013 |
| NPM-ALK signals through glycogen synthase kinase 3β to promote oncogenesis SRP McDonnell, SR Hwang, V Basrur, KP Conlon, D Fermin, E Wey, ... Oncogene 31 (32), 3733-3740, 2012 | 47 | 2012 |
| Pyrimidine tract-binding protein 1 mediates pyruvate kinase M2-dependent phosphorylation of signal transducer and activator of transcription 3 and oncogenesis in anaplastic … SR Hwang, C Murga-Zamalloa, N Brown, J Basappa, SRP McDonnell, ... Laboratory Investigation 97 (8), 962-970, 2017 | 34 | 2017 |
| Pharmacological characterization of a small molecule inhibitor of c-Jun kinase H Cho, SC Black, D Looper, M Shi, D Kelly-Sullivan, S Timofeevski, ... American Journal of Physiology-Endocrinology and Metabolism 295 (5), E1142-E1151, 2008 | 34 | 2008 |
| NPM-ALK phosphorylates WASp Y102 and contributes to oncogenesis of anaplastic large cell lymphoma CA Murga-Zamalloa, V Mendoza-Reinoso, AA Sahasrabuddhe, ... Oncogene 36 (15), 2085-2094, 2017 | 24 | 2017 |
| Molecular characterization of type I IFN-induced cytotoxicity in bladder cancer cells reveals biomarkers of resistance JL Green, RE Osterhout, AL Klova, C Merkwirth, SRP McDonnell, ... Molecular Therapy-Oncolytics 23, 547-559, 2021 | 13 | 2021 |
| Mezagitamab in systemic lupus erythematosus: clinical and mechanistic findings of CD38 inhibition in an autoimmune disease SRP McDonnell, NM Walton, C Merkwirth, F Hong, D Berg, ... Lupus Science & Medicine 11 (1), e001112, 2024 | 8 | 2024 |
| LPS-induced biomarkers in mice: a potential model for identifying insulin sensitizers CP Briscoe, D Looper, P Tran, J Herrera, SR McDonnell, BG Bhat Biochemical and biophysical research communications 361 (1), 140-145, 2007 | 7 | 2007 |
| Metabolomic analysis of NPM-ALK lymphoma cell lines SR McDonnell, A Raskind, C Ruan, CF Burant, KS Elenitoba-Johnson, ... JOURNAL OF MOLECULAR DIAGNOSTICS 14 (6), 655-655, 2012 | 1 | 2012 |
| NPM‐ALK signals through glycogen synthase kinase 3β to promote oncogenesis SRP McDonnell, E Wey, M Cheng, Z Zeng, Y Zu, K Elenitoba‐Johnson, ... The FASEB Journal 24, 421.7-421.7, 2010 | 1 | 2010 |
| Phase 1b study of the anti-CD38 antibody mezagitamab in patients with relapsed/refractory multiple myeloma AY Krishnan, KK Patel, M Mohan, S Jagannath, R Niesvizky, ... Blood Neoplasia 1 (4), 100043, 2024 | | 2024 |
| Characterization of oncolytic peptides for local bladder cancer therapy A Klova, H Tariga, S Yang, A Velentza, J Stalewski, A Kamal, ... Cancer Research 80 (16_Supplement), 588-588, 2020 | | 2020 |
| Molecular characterization of response to interferon alpha in sensitive and resistant bladder cancer models R Osterhout, J Green, S McDonnell, A Klova, A Kamal Cancer Research 80 (16_Supplement), 5857-5857, 2020 | | 2020 |
| Comparative response of bladder cancer models to interferon alpha: Recombinant protein versus adenoviral delivery. J Green, R Osterhout, S McDonnell, A Klova, A Kamal Journal of Clinical Oncology 38 (6_suppl), 531-531, 2020 | | 2020 |
| PTBP1 Interacts with PKM2 in an NPM-ALK-Dependent Manner and Contributes to the Pathogenesis of Anaplastic Large Cell Lymphoma (ALCL) J Basappa, SR Hwang, SRP McDonnell, V Basrur, C Murga-Zamalloa, ... Blood 124 (21), 3010, 2014 | | 2014 |
| Identification of PKM2 Interacting Proteins by Tandem Mass Spectrometry SR Hwang, SRP McDonnell, V Basrur, KP Conlon, D Fermin, ... The FASEB Journal 27, 1087.7-1087.7, 2013 | | 2013 |
Carlos Murga-Zamalloa M.D.University of Illinois at ChicagoVerifisert e-postadresse på uic.edu